Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Boehringer Ingelheim To Develop Cancer Drugs Aimed At Degrading Proteins

XTALKS VITALS NEWS

FDA

“We are very excited to partner with Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies,” said Dr. Alessio Ciulli, Associate Professor of Chemical and Structural Biology at the University of Dundee.

Tweetables from this article:

Tweet: Boehringer Ingelheim will develop a new class of proteolytic #cancer drugs http://ctt.ec/0y_j4+Boehringer Ingelheim will develop a new class of proteolytic cancer drugs.

Tweet: PROTACs have the potential to play a role in the treatment of cancer as well as other diseases http://ctt.ec/l3c84+PROTACs have the potential to play a role in the treatment of cancer as well as other diseases.

Share this!

July 15, 2016 | by Sarah Massey, M.Sc.

In collaboration with the researchers at the University of Dundee in Scotland, pharmaceutical company Boehringer Ingelheim will develop a new class of proteolytic cancer drugs. The drugs – named proteolysis targeting chimeric molecules (PROTACs) – will be designed to use the cell’s own housekeeping system to degrade proteins that could lead to the development of diseases like cancer.

By simultaneously binding to an ubiquitin ligase and a protein, PROTACs can trigger a cellular process capable of breaking-down the target molecule. As researchers have used RNAi screens to identify potential disease-causing proteins – including the bromodomain and extraterminal (BET) domain family – PROTACs have the potential to play a role in the treatment of cancer as well as other diseases.

“We believe our approach has the potential to fundamentally transform how we tackle protein targets to fight disease,” said Dr. Alessio Ciulli, Associate Professor of Chemical and Structural Biology at the University of Dundee. “We are very excited to partner with Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies.”



The University of Dundee is a leader in PROTAC research, and teaming up with Boehringer Ingelheim could push the technology from experimental to practical. Despite the platform’s past issues, the team could make some major headway on PROTAC development.

Research into the protein-degrading molecules began 16 years ago, but many researchers have found it challenging to identify small molecule drug candidates with sufficient binding affinity and specificity for ubiquitin ligases.

According to recent research published by Ciulli’s team, the researchers have identified a drug candidate capable of targeting a protein – named BRD4 – which has been implicated in acute myeloid leukemia, ovarian carcinoma and chronic obstructive pulmonary disease. “This is a prime example of an industry-academia collaboration to establish a disruptive new approach to drug discovery, initially developed in academia, and to enable its translation all the way to benefit patients,” said Ciulli.


Keywords: Cancer, Drug Development, Pharmaceuticals


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.